Spotlight On... Bayer, coveting top spots in animal and consumer health, may eye deals for Zoetis, Pfizer OTC; EMA warns of PML, cancer risks from Novartis' Gilenya; GSK adds Bristol's HIV pipeline assets; and more...

Bayer's position in the OTC and animal health markets has slipped thanks to some big-time consolidation moves from its rivals. But the German pharma may have a big-time move of its own up its sleeve, Reuters sources say--and it could include animal health leader Zoetis ($ZTS) or Pfizer's ($PFE) consumer offerings. More from FiercePharma

> The Europeans Medicines Agency (EMA) has added risks of basal cell carcinoma and rare brain disease PML to the product information of Novartis' ($NVS) multiple sclerosis pill Gilenya. More

> In Big Pharma's latest effort to bulk up where it's strongest, GlaxoSmithKline ($GSK) has added Bristol-Myers Squibb's ($BMY) HIV pipeline to its ViiV Healthcare portfolio. More

> Stirling Anglian Pharmaceuticals, which paid for NHS budget holders to go on a luxury trip to the German spa resort of Baden-Baden, has been heavily reprimanded by the U.K.'s industry watchdog, the Prescription Medicines Code of Practice Authority. More

> Proton-pump inhibitors, routinely prescribed to hospitalized patients, may raise the risk of death. More

And Finally... Reports have emerged that the mcr-1 gene, which confers resistance to an important antibiotic of last resort, has been found in bacteria previously collected in a handful of countries around the world. More